Pfizer Inc and BioNTech could secure emergency U.S. and European authorization for their COVID-19 vaccine next month after final trial results showed it had a 95% success rate and no serious side effects, the drugmakers said on Wednesday.
Fact‑first reporting that puts you at the heart of the newsroom. Subscribe for full access.
- Unlimited access to all premium content
- Uninterrupted ad-free browsing experience
- Mobile-optimized reading experience
- Weekly Newsletters
- MPesa, Airtel Money and Cards accepted